Propofol
Diprivan, Propofol (propofol) is a small molecule pharmaceutical. Propofol was first approved as Diprivan on 1989-10-02. It is used to treat delirium, pain, psychomotor agitation, and status epilepticus in the USA. It is known to target potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Diprivan, Propofol (discontinued: Diprivan, Propofol)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Propofol
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| DIPRIVAN | Fresenius Kabi | N-019627 RX | 1996-06-11 | 1 products, RLD, RS |
Show 1 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| diprivan | New Drug Application | 2025-09-11 |
| propofol | ANDA | 2025-09-08 |
| propofol 1% | unapproved drug other | 2023-12-27 |
| propofol injectable emulsion | ANDA | 2022-09-30 |
| propofol lipuro | unapproved drug other | 2021-12-20 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| pain | EFO_0003843 | D010146 | R52 |
| delirium | — | D003693 | R41.0 |
| psychomotor agitation | — | D011595 | — |
| status epilepticus | EFO_0008526 | D013226 | G41 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J2704 | Injection, propofol, 10 mg |
Clinical
Clinical Trials
2581 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| General anesthesia | D000768 | — | — | — | — | 1 | — | — | 1 |
| Elective surgical procedures | D017558 | — | — | — | — | 1 | — | — | 1 |
| Critical illness | D016638 | — | — | — | — | 1 | — | — | 1 |
| Nutrition therapy | D044623 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Propofol |
| INN | propofol |
| Description | Propofol is a phenol resulting from the formal substitution of the hydrogen at the 2 position of 1,3-diisopropylbenzene by a hydroxy group. It has a role as an intravenous anaesthetic, a sedative, a radical scavenger, an antiemetic and an anticonvulsant. |
| Classification | Small molecule |
| Drug class | GABAA receptor agonist;sedative;general anesthetic |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC(C)c1cccc(C(C)C)c1O |
Identifiers
| PDB | — |
| CAS-ID | 2078-54-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL526 |
| ChEBI ID | 44915 |
| PubChem CID | 4943 |
| DrugBank | DB00818 |
| UNII ID | YI7VU623SF (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Diprivan – AstraZeneca
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 69,157 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
23,561 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use